Andrew Cox, Pharm.D., MBA

For people with pain hyperacusis, everyday sounds trigger pain. The condition can lead to social isolation and worse. Treatment options are limited.

Positive results reported for pain from knee osteoarthritis among those who have obesity.

Poor balance and coordination are prominent features of Friedreich’s ataxia (FRDA). Czech researchers found that neuropsychiatric symptoms are also common among patients with FRDA.

Prescription of Neurontin (gabapentin) and other gabapentinoids has increased partly because they are viewed as a safer alternative to opioids.

Laser therapies may help with pain after a root canal, but a review of published studies shows their effectiveness can vary significantly. Further research is needed to identify the optimal approach.

As novel gene therapies emerge, there is a complex interplay among their potential benefits, the burdens they may impose and the risks involved, particularly when treating vulnerable populations such as children.

The ability to gather continuous, objective data on physical activity and upper limb movements may allow for a more comprehensive understanding of the daily functional capacities of patients with Friedereich's ataxia.

Larimar has undertaken an ongoing open-label extension study of nomlabofusp with the first enrolled patient being dosed in March 2024.

After experiencing setbacks, PTC reported positive results for vatiquinone, its selective inhibitor of 15-Lipoxygenase (15-LO) enzyme, regulator of the energetic and oxidative stress pathways that are disrupted in Friedreich ataxia

The new J-code will become effective in January and will provide reimbursement when Exparel is used in the office setting and for office-based surgeries.

Survey finds that people with chronic pain were more supportive of the policies that would expand access to medical cannabis.

A new study highlighted the potential benefits of RSV vaccination, suggesting that the vaccines could provide both individual and societal cost savings.

A review of skeletal muscle relaxants shows that they don't work for pain from osteoarthritis, neuropathic pain and other conditions. Some see an opportunity for more tailored therapeutic strategies, improving patient outcomes.

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and a large number of clinical trials enrolling people with the condition.

Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations in those 60 and older.

The future of pain medicine is characterized by treatments and technologies — including virtual reality, AI, wearable tech and psychedelics — that promise to significantly enhance patient care.

Genetic and biochemical testing are crucial for improving outcomes for patients with Friedreich ataxia, according to speakers at a symposium at the European Association of Neurology Congress.

A systemic review of corticosteroid studies finds that their anti-inflammatory effects can be beneficial in addressing peripheral injuries and as a adjuvant for treating the associated pain.

Researchers are studying how leukocyte telomere length may be associated with the progression of Friedreich's ataxia.

The approval of Skyclarys underscored the importance of sensitive outcome measures, say authors.

The two clinical trials will enroll patients recovering from surgical procedures.

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

The interplay between chronic pain and HIV can complicate treatment regimens, negatively impact functional abilities, and diminish overall quality of life for affected individuals.

Existing treatments for FDRA are limited and often fail to effectively address the root causes of the disease or manage its neurological symptoms.

The management of pain in older adults with cancer remains a significant public health concern and an unmet medical need, particularly in rural areas. This demographic often encounters specific challenges, such as limited access to healthcare services, hesitancy to talk about pain, and misunderstandings about pain management.

Given the lack of approved treatments for FA cardiomyopathy, LX2006's potential could represent a breakthrough for patients suffering from a disease characterized by severe cardiac complications.

This past May, Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare diseases, announced that its lead compound for Friedreich's Ataxia, Nomlabofusp, would participate in the START pilot program. Nomlabofusp is one of the three Center for Drug Evaluation and Research programs and one of the six programs selected by the FDA.